Vertex is also progressing IND-enabling studies for its encapsulated islet cell program, which would potentially eliminate the requirement for immunosuppression, and plans to file an IND for this ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation ...

Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted Fast Track Designation for VX-880 and that the company has initiated a clinical trial for ...

VX-880 is Vertex’s first of the two investigational programs for transplanting functional islets into patients. VX-880 is for the transplantation of islet cells alone, using immunosuppression to ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex Pharmaceuticals announced the simultaneous presentation and publication of ...

Vertex Pharmaceuticals, Inc. has paused a study of its investigational allogeneic stem cell–derived, fully differentiated pancreatic islet cell replacement therapy (VX-880) following two patient ...

BOSTON, June 20, 2025--Vertex Pharmaceuticals Incorporated ... (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial ...

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet cell therapy appears to be paying off so far.. The allogeneic human ...

Vertex is currently conducting a phase 1/2 multicenter study of the safety, tolerability, and efficacy of VX-264, a fully differentiated stem cell–derived islet cell therapy encapsulated in an ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex Pharmaceuticals announced the simultaneous presentation and publication of ...